Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has got $10m from Takeda Pharmaceutical, under the agreement signed between the two parties in May 2008.
Subscribe to our email newsletter
The payment triggers from the transferring of Alnylam‘s RNA interference drug technology to Takeda Pharma for the development of RNAi therapeutics.
Earlier, Alnylam has obtained $140m in upfront and technology transfer payments from Takeda.
Further, Anylam is also entitled to receive milestones and royalties related to the Takeda’s advancement of RNAi therapeutic products, and has retained certain product opt-in rights in the US market.
Alnylam president and chief operating officer Barry Greene said they look forward to their continued work with them in developing RNAi therapeutics on a global basis, which includes Alnylam’s opt-in right to co-develop and co-commercialize certain Takeda RNAi therapeutic products in the US market.